ondansetron has been researched along with Alcohol Drinking in 18 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study tests this hypothesis by matching nontreatment-seeking alcohol-dependent (AD) individuals with LL genotype to ondansetron and SS/SL genotypes to the SSRI sertraline, and mismatching them assessing naturalistic and bar-laboratory alcohol drinking." | 5.19 | Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study. ( Beaucage, K; Brickley, M; Clifford, JS; Fricchione, S; Haass-Koffler, CL; Kenna, GA; Leggio, L; McGeary, JE; Shoaff, JR; Swift, RM; Vuittonet, C; Zywiak, WH, 2014) |
| " late-onset classification is, however, a better predictor of response to ondansetron treatment because it might be more closely related to fundamental neurobiological processes associated with the underlying pathophysiology of alcoholism." | 3.74 | Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism. ( Ait-Daoud, N; Johnson, BA; Roache, JD; Wang, Y, 2008) |
| "Mean ondansetron exit dose was 3." | 3.01 | A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder. ( Bice, C; Holmes, T; Ivleva, E; McArdle, M; McNutt, M; Nakamura, A; Palka, J; Patel, Z; Sherwood Brown, E; Tipton, S, 2021) |
| "Ondansetron was found to augment certain stimulant, sedative, and discriminant effects of alcohol, without affecting psychomotor performance or alcohol pharmacokinetics." | 2.68 | Ondansetron alters human alcohol intoxication. ( Davidson, D; Kuznetsov, O; Swift, RM; Whelihan, W, 1996) |
| "Pretreatment with ondansetron significantly attenuated several of the subjective pleasurable effects of alcohol, and also decreased the subjective desire to drink." | 2.67 | Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers. ( Campling, GM; Cowen, PJ; Griffiths, P; Johnson, BA, 1993) |
| "Alcohol dependence is the third leading cause of preventable death in the USA." | 1.37 | Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse. ( Bond, C; Breslin, FJ; Johnson, BA; Lynch, WJ, 2011) |
| "Buspirone was without important effects on the high alcohol preferring rats." | 1.29 | Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. ( Meert, TF, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cornell, J | 1 |
| Conchas, A | 1 |
| Wang, XQ | 3 |
| Fink, JC | 1 |
| Chen, H | 1 |
| Kane, MA | 1 |
| Pilli, N | 1 |
| Ait-Daoud, N | 6 |
| Gorelick, DA | 1 |
| Li, MD | 3 |
| Johnson, BA | 9 |
| Seneviratne, C | 3 |
| Ross, H | 1 |
| Harries, B | 1 |
| Szelest, I | 1 |
| Engelbrecht, R | 1 |
| Umhau, JC | 1 |
| Sherwood Brown, E | 1 |
| McArdle, M | 1 |
| Palka, J | 1 |
| Bice, C | 1 |
| Ivleva, E | 1 |
| Nakamura, A | 1 |
| McNutt, M | 1 |
| Patel, Z | 1 |
| Holmes, T | 1 |
| Tipton, S | 1 |
| Bartolomé, I | 1 |
| Llidó, A | 1 |
| Darbra, S | 1 |
| Pallarès, M | 1 |
| Kenna, GA | 1 |
| Zywiak, WH | 1 |
| Swift, RM | 2 |
| McGeary, JE | 1 |
| Clifford, JS | 1 |
| Shoaff, JR | 1 |
| Vuittonet, C | 1 |
| Fricchione, S | 1 |
| Brickley, M | 1 |
| Beaucage, K | 1 |
| Haass-Koffler, CL | 1 |
| Leggio, L | 1 |
| Roache, JD | 4 |
| Wang, Y | 1 |
| Javors, MA | 1 |
| Liu, L | 1 |
| Penberthy, JK | 1 |
| DiClemente, CC | 1 |
| Lynch, WJ | 1 |
| Bond, C | 1 |
| Breslin, FJ | 1 |
| McBride, WJ | 1 |
| Lovinger, DM | 1 |
| Machu, T | 1 |
| Thielen, RJ | 1 |
| Rodd, ZA | 1 |
| Murphy, JM | 1 |
| Tomkins, DM | 1 |
| Le, AD | 2 |
| Sellers, EM | 3 |
| Campling, GM | 1 |
| Griffiths, P | 1 |
| Cowen, PJ | 1 |
| Meert, TF | 1 |
| Davidson, D | 1 |
| Whelihan, W | 1 |
| Kuznetsov, O | 1 |
| Prihoda, TJ | 1 |
| Hargita, ID | 1 |
| Javors, M | 1 |
| Zanca, NA | 1 |
| Higgins, GA | 1 |
| Tompkins, DM | 1 |
| Romach, MK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacological Treatment for Alcoholism[NCT00382642] | Phase 3 | 283 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Matching Genotypes and Serotonergic Medications for Alcoholism[NCT01113164] | Phase 1 | 79 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
10 trials available for ondansetron and Alcohol Drinking
| Article | Year |
|---|---|
Validation of serotonin transporter mRNA as a quantitative biomarker of heavy drinking and its comparison to ethyl glucuronide/ethyl sulfate: A randomized, double-blind, crossover trial.
Topics: Adult; Aged; Alcohol Drinking; Binge Drinking; Biomarkers; Cross-Over Studies; Ethanol; Female; Gluc | 2022 |
A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Bipolar Disorder; Double-Blind Method; Humans; Male; Middle Age | 2021 |
Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug M | 2013 |
Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Female; Genotype; Humans; Male; Middle Aged; Ondansetron; | 2014 |
Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Female; Genotype; Humans; M | 2011 |
Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers.
Topics: Adult; Affect; Alcohol Drinking; Cross-Over Studies; Double-Blind Method; Ethanol; Humans; Male; Mid | 1993 |
Ondansetron alters human alcohol intoxication.
Topics: Adult; Affect; Aged; Alcohol Drinking; Alcoholic Intoxication; Blood Pressure; Central Nervous Syste | 1996 |
Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Double-Blind Method; Female; Huma | 2001 |
Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker.
Topics: Adult; Alcohol Drinking; Alcoholism; Biomarkers; Double-Blind Method; Drug Therapy, Combination; Fem | 2001 |
Serotonin and alcohol drinking.
Topics: 1-Naphthylamine; Adult; Alcohol Drinking; Alcoholism; Animals; Double-Blind Method; Fenfluramine; Hu | 1992 |
8 other studies available for ondansetron and Alcohol Drinking
| Article | Year |
|---|---|
Incorporating ondansetron and baclofen in alcohol use disorder treatment.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Ondansetron | 2023 |
Early post-natal neuroactive steroid manipulation modulates ondansetron effects on initial periods of alcohol consumption in rats.
Topics: Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Exploratory Behavior; Finasteride; Male | 2018 |
Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.
Topics: Adult; Age Factors; Age of Onset; Alcohol Drinking; Alcoholism; Antisocial Personality Disorder; Fem | 2008 |
Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combi | 2011 |
Serotonin-3 receptors in the actions of alcohol, alcohol reinforcement, and alcoholism.
Topics: Alcohol Drinking; Alcoholism; Animals; Brain; Ethanol; Humans; Ondansetron; Receptors, Serotonin, 5- | 2004 |
Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure.
Topics: Alcohol Drinking; Animals; Drinking; Male; Mice; Mice, Inbred C57BL; Ondansetron; Rats; Rats, Wistar | 1995 |
Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Chlordiazepoxide; Citalopram; Dose-Response Relati | 1993 |
Interaction between opiate and 5-HT3 receptor antagonists in the regulation of alcohol intake.
Topics: Alcohol Drinking; Animals; Drug Synergism; Humans; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narco | 1994 |